A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder
| Autor: | Neda Koulaeinejad, Shahram Rafieian Koupaei, Samira Chaibakhsh, Atieh Modarresi |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Moderate to severe
Adult Male Treatment response medicine.medical_specialty Obsessive-Compulsive Disorder Placebo 03 medical and health sciences 0302 clinical medicine Double-Blind Method Obsessive compulsive Memantine Intervention (counseling) Internal medicine mental disorders Obsessive compulsive scale Medicine Humans Single-Blind Method Biological Psychiatry Randomized Controlled Trials as Topic Psychiatric Status Rating Scales business.industry humanities 030227 psychiatry Psychiatry and Mental health Treatment Outcome Meta-analysis Drug Therapy Combination Female business Excitatory Amino Acid Antagonists 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Psychiatry research. 282 |
| ISSN: | 1872-7123 |
| Popis: | A considerable proportion of obsessive-compulsive disorder (OCD) patients receiving first-line pharmacological therapy, fail to fully respond to treatment and continue to exhibit significant symptoms. In this systematic review, we evaluate the efficacy of memantine, as a glutamate-modulating agent, in moderate to severe OCD. Single and double blinded as well as open-label trials of memantine augmentation in adults with OCD were considered. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores were the primary outcome measure. The electronic databases of PubMed, Scopus, Embase and Google Scholar were searched for relevant trials using keywords ‘obsessive-compulsive disorder OR OCD’ AND ‘memantine’. The meta-analysis of eight studies involving 125 OCD subjects receiving memantine augmentation exhibited a significant overall mean reduction of 11.73 points in Y-BOCS scores. The categorical analysis of treatment response (a minimum of 35% reduction in Y-BOCS) in four double-blind placebo-controlled studies indicated that OCD patients receiving memantine augmentation were 3.61 times more likely to respond to treatment than those receiving placebo. We found that 20 mg/day memantine augmentation to first-line pharmacological treatment for a period of at least 8 weeks is a safe and effective intervention for moderate to severe OCD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect